Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Instil Bio, Inc.NASDAQ: TIL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $4.2M (cash outflow) fell 85.1% year over year, behind the -39.3% change in trailing-twelve-month net income. Sequentially, it fell 48.7% from the prior quarter. Over 3 fiscal years it compounded at -31.6% a year.
Context
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$7.8M (-89.1%) for the fiscal year ending Dec 2026, a slowdown from the -3.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.2M-48.7% QoQ
- Last fiscal yearDec 2025
- -$71.37M-3.7% YoY
- LTMMar 2026
- -$47.38M-39.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -85.1% | -88.9% | -3.8 pp |
| 1 year | -3.7% | -89.1% | -85.3 pp |
| 3-year CAGR | -31.6% | +1.1% | +32.7 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (71.37M) USD
- Year-over-year change
- +3.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (71.37M) | +3.7% |
| FY2024 | 2024-12-31 | (74.14M) | +52.5% |
| FY2023 | 2023-12-31 | (156.09M) | +30.1% |
| FY2022 | 2022-12-31 | (223.18M) | -42.3% |
| FY2021 | 2021-12-31 | (156.79M) | — |
Net Income vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -39.3% is the 6th highest of 9, against a peer median of -18.6%.
- Over three fiscal years its annual growth of -31.6% compares with a peer median of -4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $342.56M USD | +319.3% | +88.7% | 4571.1% | |
| LTM Mar 2026 | $124.13M USD | -44.6% | -16.7% | — | |
| LTM Mar 2026 | $113.22M USD | -48.4% | +6.6% | — | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $49.87M USD | -29.4% | -21.8% | 4987.4% | |
| LTM Mar 2026 | $47.38M USD | -39.3% | -31.6% | — | |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | CA$35.52M CAD | +12.8% | +16.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M USD | -67.7% | -30.2% | 288.3% |
| Peer median (excluding TIL) | — | -18.6% | -4.0% | 4571.1% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| Deferred Income Tax | 710K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.2M | 30.44M | 18.17M | 17.26M | 8.69M |
| Change in Working Capital | 4.36M | (9.57M) | (9.02M) | (12.61M) | (560K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (3.4M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.86M | (1.81M) | (1.13M) | (556K) | 116K |
| Other Working Capital | 499K | (7.76M) | (7.89M) | (12.05M) | 2.72M |
| Other Non-Cash Items | 636K | 16.15M | 60.15M | 10.18M | 26.09M |
| Operating Cash Flow | (122.14M) | (180.16M) | (82.03M) | (55.7M) | (36.62M) |
| Capital Expenditures | (57.83M) | (84.59M) | (20.66M) | (10M) | 0 |
| Acquisitions (Net) | 0 | 1.17M | 0 | 0 | 432K |
| Purchases of Investments | (1.11B) | (666.22M) | (301.47M) | (135.6M) | (100.86M) |
| Sales of Investments | 691M | 865.35M | 361.7M | 198.71M | 135.9M |
| Other Investing Activities | 0 | (1.17M) | 1.56M | 866K | 0 |
| Investing Cash Flow | (474.4M) | 114.54M | 41.13M | 53.97M | 25.48M |
| Debt Repayment | 0 | 70.34M | 8.08M | 2.76M | 6.61M |
| Common Stock Issued | 339.02M | 1.55M | 0 | 0 | 853K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.69M | 0 | 0 | (1.01M) | (172K) |
| Financing Cash Flow | 393.16M | 71.89M | 8.08M | 1.76M | 7.29M |
| Effect of Forex Changes | (304K) | (637K) | (201K) | (94K) | 20K |
| Net Change in Cash | (203.67M) | 5.63M | (33.02M) | (61K) | (3.83M) |
| Free Cash Flow | (179.97M) | (264.75M) | (102.69M) | (65.7M) | (36.62M) |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.